Apixaban and oral implications by López Galindo, Mónica Paula & Bagán Sebastián, José Vicente
J Clin Exp Dent. 2015;7(4):e528-34.                                                                                                                                                                                   Apixaban and oral implications
e528
Journal section: Oral Medicine and Pathology                      
Publication Types: Review
Apixaban and oral implications
Monica Lopez-Galindo 1, Jose V. Bagán 2
1 Associate Professor, PhD, Dentistry Department, European University of Valencia, Valencia, Spain
2 Dentistry Department, University of Valencia, Valencia, Spain. Chairman of Oral Medicine, University of Valencia. Head of the 
Department of Stomatology and Maxillofacial Surgery,Valencia University General Hospital, Valencia, Spain
Correspondence:
C/ Duque de Calabria 17-1
46005-Valencia, Spain
mopauloga@gmail.com
Received: 03/11/2014
Accepted: 09/03/2015
doi:10.4317/jced.52470
http://dx.doi.org/10.4317/jced.52470
Abstract 
Background: Thrombotic disorders remain a leading cause of death in the Western world, and in this regard a 
number of anticoagulation treatment have been used, including heparins, fondaparinux, vitamin K antagonists 
(warfarin, acenocoumarol), and new oral anticoagulants such as apixaban.
For years there has been great controversy regarding the use of anticoagulants in planning dental treatments that 
imply bleeding. The main concerns about using new oral anticoagulants in invasive dental procedures are bleeding 
due to the lack of an antidote, and the thrombotic risk of the disease for which anticoagulation was indicated in the 
first place.
Material and Methods: A literature search was conducted through May 2014 using the keyword “apixaban” for 
publications in the ISI Web of Knowledge. The search was extended to other databases (PubMed, Scopus and the 
Cochrane Library). 
Results: Based on the results of the different studies, apixaban seems to be a good alternative to conventional anti-
coagulation and a reasonable treatment option, though its main and most common adverse effect is bleeding. Dose 
adjustment is needed in some patients, though regular laboratory monitoring is not required. The use of the drug in 
different patient populations will define its final indications and doses.
Conclusions: Regarding the use of apixaban in the dental setting, there is a compelling need for further clinical 
studies in order to establish more evidence-based guidelines for patients requiring antithrombotic treatment.
Key words: Apixaban, dental treatment, dental implications.
Introduction
Thrombotic disorders remain a leading cause of death 
in the Western world, and in this regard a number of 
anticoagulation treatment have been used, including 
unfractionated heparin, low molecular weight heparins 
(semuloparin, enoxaparin), fondaparinux, vitamin K an-
tagonists (warfarin, acenocoumarol) and new oral anti-
coagulants (1).
Heparins in general and fondaparinux require subcuta-
neous administration. Vitamin K antagonists can be ad-
ministered via the oral route but have other drawbacks 
such as drug and diet interactions, a slow onset of thera-
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peutic effects, the need for regular International Norma-
lized Ratio (INR) monitoring and dose adjustments, and 
a narrow therapeutic index (2).
The new oral anticoagulants, including apixaban, do not 
have these disadvantages (3).
Apixaban is an orally active, direct selective factor Xa 
inhibitor. It reversibly and selectively inhibits the activa-
tion site of factor Xa (4,5), a trypsin-like serine protease 
which is the final enzyme in the coagulation cascade, 
being responsible for fibrin clot formation. Factor Xa 
serves as the link between the extrinsic and intrinsic 
coagulation pathways. It exerts antithrombotic and anti-
coagulant effects by diminishing the conversion of pro-
thrombin to thrombin (6). Apixaban indirectly inhibits 
platelet aggregation by reducing thrombin generation 
(7). It has a favorable safety and efficacy profile also in 
special populations (elderly subjects, obese individuals, 
patients with renal and liver dysfunction) (8), and can be 
administered with or without food (4).
Direct inhibition of factor Xa attenuates the generation of 
thrombin, whilst direct inhibition of thrombin affects its ac-
tivity. Accordingly, the inhibition of factor Xa, produced for 
example by apixaban, preserves hemostatic function (9).
Apixaban has high oral bioavailability (approximately 
52%), and reaches peak plasma concentrations approxi-
mately three hours after administration, with a half-
life of about 12 hours. It is predominantly eliminated 
through metabolic pathways and non-renal mechanisms, 
with a minimal potential for drug interactions and the 
formation of reactive metabolites (4,9). About 25% of 
the drug is excreted in urine (10). The pharmacokinetic 
profile of apixaban is compatible with dosing twice or 
once a day (11).
Cytochrome P450 isoenzyme 3A4 (CYP3A4) and sulfo-
transferase F1A1 appear to be the major enzymes invol-
ved in metabolizing apixaban to an inactive circulating 
metabolite. Strong inhibitors of CYP3A4 (such as ma-
crolide antibiotics, protease inhibitors and azole antifun-
gals) substantially increase the drug levels and should 
not be taken in combination with apixaban (6). Howe-
ver, the effect of apixaban is independent of vitamin K 
intake (12).
There seems to be little evidence on the reversal of the 
effects of apixaban (13).
For years there has been great controversy regarding the 
use of anticoagulants in planning dental treatments that 
imply bleeding. The main concerns about using new oral 
anticoagulants in invasive dental procedures are blee-
ding due to the lack of an antidote, and the thrombotic 
risk of the disease for which anticoagulation was indica-
ted in the first place (14).
Apixaban may represent a good alternative to traditional 
anticoagulation, though due consideration is required 
not only of the benefits but also of the possible inconve-
niences associated with its use.
Objetive
To evaluate the use of apixaban in the dental setting be-
fore and after dental extraction and/or surgery.
Material and Methods 
A literature search was conducted through May 2014 
using the keyword “apixaban” for publications in the ISI 
Web of Knowledge. No lower limit was set. The search 
resulted in 403 papers, and was then limited to articles in 
English and preferably clinical studies in adult patients 
(≥ 18 years of age). The search focused on clinical trials, 
but other articles were also taken into account for rele-
vant information about apixaban.
The search was extended to other databases (PubMed, 
Scopus and the Cochrane Library). The PubMed search 
involved “apixaban” in the title, and the activated filters 
were: clinical trial, humans, and English in the advan-
ced search. The Scopus search in turn involved “apixa-
ban” in the title, abstract and keywords in the advanced 
search, with restriction to the English language. Lastly, 
the Cochrane Library search was activated with the word 
“apixaban” from 2009 to 2014.
Regarding the relationship between apixaban and den-
tistry, other searches were performed in the ISI Web of 
Knowledge, PubMed, Scopus and the Cochrane Library, 
using the words “apixaban” and “dental treatment”, 
“apixaban” and “oral consequences”, and “apixaban” 
and “dental implications”.
The main issue in dental practice is to design a protocol 
for using the drug, trying to establish whether apixaban 
should be suspended or not when performing dental ex-
traction, followed by reintroduction after the surgical 
procedure.
Results
Apixaban has been used for preventing thromboembolic 
events in acutely ill non-surgical patients (15) and fo-
llowing knee or hip replacement surgery (16,17), as well 
as in patients with acute coronary syndrome (ACS) (18) 
and in cases of atrial fibrillation (AF) (19,20). 
Why is it so important to prevent thromboembolic 
events? Venous thromboembolism (VTE) is a common 
complication in surgical patients and also in acutely ill 
non-surgical patients. It is also a potentially fatal com-
plication (21). Patients undergoing orthopedic surgery 
(hip or knee replacement) are at a high risk of develo-
ping postoperative VTE complications. The provision of 
thromboprophylaxis after hospital discharge has reduced 
in the rates of symptomatic and asymptomatic VTE (22). 
In this regard, correct anticoagulation is essential in or-
der to decrease patient morbidity and mortality (23).
Apixaban has been used on a prophylactic basis in pa-
tients undergoing hip or knee replacement surgery to 
reduce the incidence of VTE. Despite such preventive 
measures, however, symptomatic VTE occurs in 2-4% of 
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the cases during the first three months after surgery, and 
subclinical deep-vein thrombosis is recorded in approxi-
mately 15-20% of patients soon after surgery (23).
Several clinical trials on apixaban have been published 
since 2007, starting with the APPROPOS study, in which 
the drug was used to prevent VTE 12-24 hours after total 
knee replacement surgery. A total of 1238 patients parti-
cipated in this randomized, multicenter, 8-arm, parallel 
group phase II trial (11) (Table 1).
Other studies on the prevention of thromboembolic com-
plications after VTE have been the ADVANCE (2009), 
ADVANCE-2 (2010) and ADVANCE-3 (2010) studies, 
and the ADOPT trial (2011), involving the largest num-
ber of patients to date (n=6528). The AMPLIFY-EXT 
trial in turn was published in 2012, with the participa-
tion of 2486 patients. The ADVANCE, ADVANCE-2 
and ADVANCE-3 trials included 3195, 3057 and 5407 
patients, respectively (15-17,24,25). 
Most of the studies on the prevention of thromboembo-
lic complications after VTE have been phase III trials 
(ADVANCE, ADVANCE-2 and ADVANCE-3). The ex-
ception has been the APPOPOS study, which was a pha-
se II trial. AMPLIFY-EXT and ADOPT failed to specify 
the trial phase involved (11,15-17,24,25).
The mean patient age in the different trials was 66 years 
(ADVANCE), 67 years (ADVANCE-2), 60 years (AD-
VANCE-3), 67 years (ADOPT) and 57 years (AMPLI-
FY-EXT). In the APPROPOS trial the mean patient age 
was 66.7 years.
In most of the mentioned studies, apixaban was used 
to prevent thromboembolism after knee (ADVANCE, 
ADVANCE-2, APPROPOS) or hip replacement surgery 
(ADVANCE-3), or in acutely ill non-surgical patients 
(ADOPT). In the AMPLIFY-EXT study, apixaban was 
used in patients with VTE who had completed 6-12 
months of anticoagulation therapy and for whom there 
was a clinically balanced decision between either conti-
nuing or interrupting anticoagulation therapy.
Regarding the treatment used in each trial, the patients 
received oral apixaban at a dose of 2.5 mg twice a day 
(b.i.d.) or enoxaparin via the subcutaneous route at do-
ses of 30 mg b.i.d. (ADVANCE) or 40 mg once a day 
(ADVANCE-2, ADVANCE-3, ADOPT). Several apixa-
ban doses were used in the 8-arm APROPOS study (5, 
10 and 20 mg once a day, as well as 2.5, 5 and 10 mg 
b.i.d.). Warfarin was also administered (INR 1.8-3) to 
another group of patients. Enoxaparin was used subcuta-
neously at a dose of 30 mg b.i.d. The most recent study, 
the AMPLIFY-EXT trial, only involved two different 
apixaban doses of 2.5 or 5 mg b.i.d., without comparison 
versus enoxaparin.
The duration of treatment was 10-14 days in the AD-
VANCE, ADVANCE-2 and APPROPOS trials, and was 
a little longer in the ADVANCE-3 study (35 days). The 
ADOPT trial contemplated treatment for 30 days in the 
apixaban group and for 6-14 days in the enoxaparin 
group. The longest treatment duration corresponded to 
the AMPLIFY-EXT study (12 months).
Regarding the results obtained by the different studies 
in the prevention of VTE, the authors of the APROPOS 
trial concluded that apixaban might be effective in pre-
venting VTE after total knee replacement surgery, ad-
ministered at doses of 2.5 mg b.i.d. or 5 mg daily. This 
phase II trial led to selection of the apixaban dose used 
in the phase III ADVANCE trial.
The conclusion of the ADVANCE study on the preven-
tion of VTE after knee replacement surgery was that 
apixaban resulted in fewer cases of clinically relevant 
bleeding than enoxaparin, with a similar adverse events 
profile.
In the ADVANCE 2 trial, apixaban 2.5 mg b.i.d. was 
seen to be more effective than enoxaparin 40 mg daily, 
with no increase in bleeding risk (or with a similar inci-
dence of major bleeding), in preventing VTE after knee 
replacement surgery.
In the ADVANCE 3 study, the results were similar to 
those obtained in the ADVANCE 2 trial - apixaban be-
ing associated to lower VTE rates, with no increase in 
bleeding. 
In the AMPLIFY-EXT study, the findings suggested 
apixaban to be superior to placebo in reducing VTE, 
with no increased risk of major bleeding.
In the ADOPT trial (involving non-surgical patients), an 
extended course of apixaban to prevent thrombosis was 
not found to be superior to a shorter period with enoxa-
parin. Apixaban was associated with significantly more 
major bleeding events than enoxaparin. However, this 
trial did not provide evidence justifying extended pro-
phylaxis in a broad population of non-surgical patients 
after hospital discharge.
Regarding the use of apixaban in acute coronary syn-
drome (ACS), three studies should be commented: the 
APPRAISE, APPRAISE 2 and APPRAISE-J trials. 
Acute coronary syndrome includes both acute myocar-
dial infarction and unstable angina, and is a worldwide 
leading cause of cardiovascular mortality (26).
Patients with ACS continue to experience recurrent is-
chemic events despite revascularization and ongoing 
antiplatelet therapy. Other management alternatives, in-
cluding apixaban, are therefore investigated (27).
The APPRAISE trial was published in 2009 and invol-
ved 1715 patients with a mean age of 60 years. This was 
an international, multicenter, double-blind, randomized, 
placebo-controlled, dose-ranging study and the largest 
global phase II trial published up until then. It was de-
signed to assess the efficacy and safety of apixaban in 
preventing recurrent ischemic events after ACS (27).
The APPRAISE 2 trial in turn was published in 2011, 
and a total of 7392 patients took part. The mean age was 
67 years. This was a double-blind, randomized, placebo-
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controlled, phase III trial comparing apixaban with pla-
cebo, in addition to antiplatelet therapy, in patients with 
recent ACS and at least two additional risk factors for 
recurrent ischemic events (28).
The APPRAISE-J study was published in 2013, and 
comprised a limited sample of 150 Japanese patients. 
This was a placebo-controlled, randomized, double-
blind phase II study conducted at the same time as the 
APPRAISE 2 trial and involving a design similar to that 
of the APPRAISE study (26).
The APPRAISE study was the first phase II trial to ex-
plore several apixaban doses in patients with ACS ad-
ministered concomitant treatment in the form of aspirin 
in most cases (≤ 165 mg per day) and clopidogrel. The 
clopidogrel dose was not specified. The apixaban doses 
were 2.5 mg b.i.d., 10 mg once daily, 10 mg b.i.d., or 20 
mg daily (27).
In the APPRAISE 2 trial, apixaban was used at a dose of 
5 mg b.i.d. compared with placebo and added to standard 
antiplatelet therapy (aspirin or aspirin plus any P2Y12 
receptor antagonist - predominantly clopidogrel). Some 
patients with an estimated creatinine clearance of < 40 
ml/min. at the time of randomization were randomly as-
signed to receive 2.5 mg of apixaban b.i.d. or matching 
placebo (28).
In the APPRAISE-J trial, the patients received apixaban 
2.5 or 5 mg b.i.d. or matching placebo, as well as stan-
dard antiplatelet therapy (aspirin or aspirin plus a thieno-
pyridine such us clopidogrel or ticlopidine) (26).
The duration of the treatment differed in each study. The-
rapy in the APPRAISE trial lasted 26 weeks (a little over 
6 months), versus 241 days (8 months) in the APPRAI-
SE 2 study and 24 weeks (a little under 6 months) in the 
APPRAISE-J trial.
A dose-related increase in bleeding was observed in the 
APPRAISE study, together with a trend towards fewer 
ischemic events following the addition of apixaban to 
antiplatelet therapy in patients with recent ACS. In the 
APPRAISE 2 trial, 5 mg of apixaban b.i.d., added to an-
tiplatelet therapy in high risk patients after ACS, resulted 
in an increased number of major bleeding events, without 
a significant reduction in recurrent ischemic phenomena. 
This study was terminated prematurely as a result. In the 
APPRAISE-J trial, the bleeding profile with apixaban 
was similar to that found in the APPRAISE study; it was 
terminated before completion not because of the results 
of the study itself, but because of the recommendations 
of the DSMC (Data and Safety Monitoring Committee) 
for the concurrent APPRAISE-2 trial.
The prevention of thromboembolic events in patients 
with atrial fibrillation (AF) is crucial, because these 
individuals are at an increased risk of stroke (29,30). 
Atrial fibrillation is the most common chronic arrhyth-
mia (6). Patients with AF have a higher risk of develo-
ping heart failure, poorer quality of life, and cognitive 
impairment (6), i.e., AF and its potential complications 
are associated to increased mortality and morbidity risk 
(12,31), and constitute a significant health and econo-
mic problem (32). Chronic kidney disease carries a high 
risk of cardiovascular disease, including AF (33). Some 
authors have concluded that the oral new anticoagulants 
are more cost-effective than warfarin, and apixaban has 
been pointed to as the preferred drug in this respect (34). 
Other authors have reported the new oral anticoagulants 
to be more efficacious than warfarin in preventing stroke 
and systemic embolism in patients with AF (35,36).
The studies addressing AF have been the AVERROES 
and ARISTOTLE-J trials published in the year 2011. 
The ARISTOTLE study (2012) was the trial with the lar-
gest number of patients (n=18,201. The ARISTOTLE-J 
study was a phase II and partially blinded trial, whe-
reas ARISTOTLE and AVERROES were double-blind, 
double-dummy phase III trials. The three studies were 
randomized, and the mean patient age was 70 years (23-
25). The duration of the trials was 12 weeks in the case 
of the ARISTOTLE-J study, 1.1 years for AVERROES, 
and 1.8 years in the case of the ARISTOTLE trial.
The treatment administered in the three mentioned stu-
dies was apixaban 2.5 mg b.i.d. or 5 mg b.i.d.. Apixaban 
was compared with aspirin (18-324 g per day) in the 
AVERROES trial, dose-adjusted warfarin (to achieve 
target INR 2-3) in the ARISTOTLE study, and dose-
adjusted warfarin in the ARISTOTLE-J trial (to achieve 
target INR 2-3, or 2.0-2.6 in the case of age ≥ 70 years).
The results obtained in the AVERROES trial showed 
apixaban to be superior to aspirin, with a reduction of 
the risk of stroke or systemic embolism, and with no 
significant increase in the risk of major bleeding or in-
tracranial hemorrhage. The clear benefit of apixaban led 
the DSMC to recommend early termination of the study. 
In the ARISTOTLE trial, apixaban was found to be su-
perior to warfarin, causing less bleeding and resulting 
in lesser mortality. In the ARISTOTLE-J trial, apixaban 
was seen to be well tolerated, with fewer cases of major 
and clinically relevant non-major bleeding versus warfa-
rin over 12 weeks.
We have found very few results on new oral anticoagu-
lants in relation to dental practice. There seems to be a 
genuine need for clinical studies, with a view to esta-
blishing management protocols for these drugs. The risk 
posed by new oral anticoagulants in dentistry is associa-
ted to procedures in which bleeding is involved, such 
as dental extractions, dental and/or periodontal surgery, 
etc. As general rules in the dental setting, it is prefera-
ble for surgery to be done in the morning rather than in 
the afternoon, and preferably at the start of the week, in 
order to offer the patient adequate management in the 
case of bleeding. Dental extraction should be as scantly 
traumatic as possible. After extraction, hemostatic mea-
sures must be adopted to help bleeding control, such as 
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absorbable hemostatic dressings in the form of oxidized 
cellulose (Surgicel®), collagen sponges (Haemocolla-
gel®), or reabsorbable gelatin sponges (Spongostan®). 
It is also advisable to suture the extraction socket and 
apply compressive gauzes impregnated with tranexamic 
acid (14,37).
The main inconvenience with the use of apixaban is the 
lack of an antidote (13,38).
Discussion
Regarding the use of apixaban for preventing thromboe-
mbolic complications after VTE, ACS or AF, the most 
widely accepted dosage appears to be 2.5 or 5 mg b.i.d. 
The only uncertainty in this regard is deciding which is 
the most convenient dose.
The trials on the prevention of thromboembolic compli-
cations after VTE had a duration of 10-14 days, 35 days 
or 12 months, i.e., covering a broad range. The trials in 
which apixaban was used in application to ACS had a 
treatment duration of about 6 months, while the admi-
nistration of apixaban in AF lasted approximately 12 
months (20 months in the AVERROES trial). The dura-
tion of the treatments varies greatly among the different 
trials, and this may influence assessment of the useful-
ness of apixaban in a positive or negative way. In this 
regard, doubts may arise as to whether such durations of 
treatment are sufficient or, contrarily, if long-term use of 
the drug may give rise to clinical side effects.
In some cases, standard antiplatelet therapy (aspirin or 
aspirin plus thienopyridine) is added to apixaban, as in 
the APPRAISE, APPRAISE 2 or APPRASE-J trials, and 
it would be very useful to know whether such therapy 
is necessary or not. Based on the trials using apixaban 
for the prevention of ACS, it seems that major bleeding 
events occurred without a significant reduction in recu-
rrent ischemic events; this is why some trials were in-
terrupted before completion. It appears that antiplatelet 
therapy should not be added in these cases.
With respect to the studies on use of apixaban in AF, the 
drug was compared with aspirin or warfarin, and was not 
used concomitantly with these agents. The results refe-
rred to apixaban were encouraging and reflected clear 
benefit of apixaban over aspirin or warfarin or enoxa-
parin.
When new oral anticoagulants are administered to pa-
tients requiring dental procedures that imply bleeding, 
several aspects should be taken into account: the in-
vasiveness of the dental procedure, the half-life of the 
drug, renal function (39), comorbidities and the risk of 
thromboembolic events (37). The invasiveness of the 
dental treatment is related to bleeding risk; according to 
Spyropoulos (40), minor bleeding risk is found in simple 
extractions (< 3 teeth) and surgery lasting less than 45 
minutes, while major bleeding risk is found in multiple 
extractions (> 3 teeth), surgery lasting more than 45 mi-
nutes, and head and neck cancer surgery. In relation to 
renal function, van Ryn et al. (39) used creatinine clea-
rance (ml/min) to define direct anticoagulant suspension 
times. They established that for a half-life of 13 hours 
(apixaban has a half-life of about 12 hours), the time 
from last drug dose to surgery is 24 hours for lesser blee-
ding risk and 2-4 days for high bleeding risk. According 
to a first approach made by Spyropoulos and Douketis 
(40), the reintroduction of apixaban in the case of low 
bleeding risk surgery should be 24 hours post-surgery, 
at a dose of 5 mg b.i.d. In the case of high bleeding risk 
surgery, apixaban should be resumed 2-3 days after sur-
gery at a dose of 5 mg b.i.d., with the possibility of redu-
cing the dose to 2.5 mg b.i.d. in patients at high risk of 
thromboembolism.
Conclusions
Based on the results of the different studies, apixaban 
seems to be a good alternative to conventional anticoa-
gulation and a reasonable treatment option, though its 
main and most common adverse effect is bleeding. Dose 
adjustment is needed in some patients, though regular 
laboratory monitoring is not required. The use of the 
drug in different patient populations will define its final 
indications and doses.
Regarding the use of apixaban in the dental setting, there 
is a compelling need for further clinical studies in order 
to establish more evidence-based guidelines for patients 
requiring antithrombotic treatment.
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